Welcome to LookChem.com Sign In|Join Free
  • or
5-bromo-2-nitro-N-(4-hydroxyphenyl)aniline is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

68142-10-9

Post Buying Request

68142-10-9 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

68142-10-9 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 68142-10-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,8,1,4 and 2 respectively; the second part has 2 digits, 1 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 68142-10:
(7*6)+(6*8)+(5*1)+(4*4)+(3*2)+(2*1)+(1*0)=119
119 % 10 = 9
So 68142-10-9 is a valid CAS Registry Number.

68142-10-9Downstream Products

68142-10-9Relevant academic research and scientific papers

Design, synthesis and evaluation of some 1,6-disubstituted-1H-benzo[d]imidazoles derivatives targeted PI3K as anticancer agents

Ding, Huai-Wei,Yu, Lu,Bai, Meng-xuan,Qin, Xiao-Chun,Song, Man-tong,Zhao, Qing-Chun

, (2019)

Phosphatidylinositol 3-kinase (PI3K) pathway regulates various cellular processes, such as proliferation, growth, autophagy and apoptosis. Class I PI3K is frequently mutated and overexpressed in a lot of human cancers and PI3K was considered as a target for therapeutic treatment of cancer. In this study, we designed and synthesized a series of 1,6-disubstituted-1H-benzo[d]imidazoles derivatives and evaluated their anticancer activity and the compound 8i was identified as a lead compound. Compound 8i with the most potent antiproliferative activity was selected for further biological mechanism. The PI3K kinase assay have shown potent efficiency against four subtypes of PI3K with an IC50 of 0.5–1.9 nM. Molecular docking showed a possible formation of H-bonding with essential amino acid residues. Meanwhile, western blot assay indicated that 8i inhibited cell proliferation via suppression of PI3K kinase activity and subsequently blocked PI3K/Akt pathway activation in HCT116 cells. In addition, 8i could inhibit the migration and invasion ability of HCT116 cells and could induce apoptosis of HCT116 cells.

1, 6-disubstitution-benzo five-membered heterocycle derivative and application thereof

-

Paragraph 0065-0070, (2019/12/25)

The invention belongs to the technical field of medicine, and discloses a novel 1, 6-disubstitution-benzo five-membered heterocycle compound and a preparation method and application thereof. The structural formula of the compound is shown in a formula I (please see the specification for the formula I), wherein R1, R2, R3, X, Y, Z, n and the circle are stated as the claim and the specification. Thecompound has good anti-tumor activity, can be used as a treatment agent for treating tumors in the field of preparation of anti-tumor drugs, and meanwhile can also serve as PI3K, PI4K and m-TOR inhibitors.

Synthesis and in vitro evaluation of diverse heterocyclic diphenolic compounds as inhibitors of DYRK1A

Zhou, Qingqing,Reekie, Tristan A.,Abbassi, Ramzi H.,Indurthi Venkata, Dinesh,Font, Josep S.,Ryan, Renae M.,Munoz, Lenka,Kassiou, Michael

, p. 5852 - 5869 (2018/11/10)

Dual-specificity tyrosine phosphorylation-related kinase 1A (DYRK1A) is a dual-specificity protein kinase that catalyses phosphorylation and autophosphorylation. Higher DYRK1A expression correlates with cancer, in particular glioblastoma present within the brain. We report here the synthesis and biological evaluation of new heterocyclic diphenolic derivatives designed as novel DYRK1A inhibitors. The generation of these heterocycles such as benzimidazole, imidazole, naphthyridine, pyrazole-pyridines, bipyridine, and triazolopyrazines was made based on the structural modification of the lead DANDY and tested for their ability to inhibit DYRK1A. None of these derivatives showed significant DYRK1A inhibition but provide valuable knowledge around the importance of the 7-azaindole moiety. These data will be of use for developing further structure-activity relationship studies to improve the selective inhibition of DYRK1A.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 68142-10-9